Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N), opens new tab vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 ; NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the ...

EU approves first vaccine against common respiratory virus. London (AFP) – The European Commission has followed the United States in approving the world's first vaccine for the Respiratory ...

While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply.

Moderna's mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults.

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49. NEW YORK, April 01, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today ...

The EU's health regulator is expected to decide in the first half of 2026 on the expanded use of Arexvy, GSK said, adding that it was working on making similar applications to U.S. and Japanese ...